BNTX
NASDAQBioNTech SE
Price$116.56+28.68 (+32.63%)
2026-05-192026-08-21
News · 26 weeks64+40%
2026-03-012026-08-23
Mix2090d
- Other7(35%)
- SEC Filings7(35%)
- Insider2(10%)
- Earnings2(10%)
- Analyst1(5%)
- Leadership1(5%)
Latest news
25 items- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- PRBioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNTech’s leadership in novel-novel combination treatment strategiesUpdated overall survival data for gotistobart from the PRESERVE-003 Phase 3 clinical trial will add to the growing body of evidence for this chemotherapy-free treatment approach in the second- and later-line treatment of advanced squamous non-small cell lung cancer following prior immunotherapyBioNTech is advancing a diversified development program in lung cancer treatment spanning more than 16 ongoing clinical trials across subtype
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- PRBioNTech Announces Second Quarter 2026 Financial Results and Corporate UpdateGuido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer, taking office by February 1, 2027, at the latestAdvanced diversified pipeline now with 14 ongoing pivotal clinical trials and more than ten novel-novel combinations across major tumor types Multiple milestones achieved in 2026, including initiation of six pivotal trials - five for pumitamig and one for B7-H3-targeting ADC candidate elfetabart drozuntecan; upcoming 2026 catalysts include three late-stage readouts expected across immunomodulators, antibody-drug conjugate and mRNA cancer immunotherapies Pumitamig in combination with chemotherapy showed encouraging efficacy in first line non-small cell lun
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- PRBioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive OfficerMainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer ("CEO"), who will take office by February 1, 2027, at the latest. Succeeding Prof. Ugur Sahin, M.D., Guido Oelkers will join BioNTech from the global Nasdaq Stockholm-listed biopharmaceutical company Swedish Orphan Biovitrum AB (STO: SOBI, "Sobi"), where he has served as CEO since 2017. Guido Oelkers is a seasoned CEO and strategic leader with over 30 years of experience in the biotechnology and pharmaceutical industries. He has a strong track record in trans
- SECAmendment: SEC Form 20-F/A filed by BioNTech SE20-F/A - BioNTech SE (0001776985) (Filer)
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- PREuropean Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European UnionData indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globallyVaccine demonstrates a favorable safety and efficacy profile Shipping will begin soon to ensure rapid access of this season’s vaccine NEW YORK and MAINZ, GERMANY, July 29, 2026 — Pfizer Inc. (NYSE:PFE, "Pfizer")) and BioNTech SE (NASDAQ:BNTX, "BioNTech")) announced today that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for activ
- PREuropean Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European UnionData indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globally Vaccine demonstrates a favorable safety and efficacy profile Shipping will begin soon to ensure rapid access of this season’s vaccine Pfizer Inc. (NYSE:PFE, "Pfizer")) and BioNTech SE (NASDAQ:BNTX, "BioNTech")) announced today that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-1
- PRBioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026MAINZ, Germany, July 21, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via th
- INSIDERSEC Form 3 filed by new insider Low-Friedrich Iris Katharina3 - BioNTech SE (0001776985) (Issuer)
- INSIDERSEC Form 3 filed by new insider Schaffert Susanne3 - BioNTech SE (0001776985) (Issuer)
- PRThe New War on Cancer: Four Public Companies Helping Lead a Medical RevolutionDENVER, June 25, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Cancer treatment is undergoing one of the most significant transformations in modern medical history. For decades, physicians relied primarily on surgery, radiation, and chemotherapy. While those therapies have saved countless lives, a new generation of biotechnology companies is working to make cancer treatment smarter, more targeted, and potentially more effective. Rather than simply attacking rapidly dividing cells, researchers are developing therapies designed to identify specific genetic mutations, harness the immune system, and deliver treatments directly to cancer cells while minimizing damage to healthy tissue. Seve
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- PRThe Multi-Billion-Dollar Search for Better Glioblastoma TreatmentsDENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. Yet one of oncology's greatest challenges remains largely unsolved. Glioblastoma. Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with the difficulty of delivering therapies into the brain, has mad
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- PRGlobal Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 TrialFirst investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of carePumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypesPumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively
- ANALYSTBioNTech upgraded by UBS with a new price targetUBS upgraded BioNTech from Neutral to Buy and set a new price target of $135.00
- ANALYSTBernstein initiated coverage on BioNTech with a new price targetBernstein initiated coverage of BioNTech with a rating of Mkt Perform and set a new price target of $96.00
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- PRBioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual MeetingPumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapyGotistobart Phase 2 overall survival data in patients with platinum-resistant ovarian cancer add to the growing body of evidence supporting its potential as a chemotherapy-free treatment optionContinued advancement of late-stage oncology pipeline with 25+ Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials as well as novel-novel combination trials across major cancer types MAINZ, Germany, May 22, 2026 – BioNTech SE (NASDAQ:BNTX, "BioNTech"
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- PRBioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026MAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) held its Annual General Meeting ("AGM") today. A total of 92 per cent of the share capital was represented at the virtual assembly. All resolutions proposed on the agenda items put to the vote at today's AGM were approved by a majority of the shareholders. BioNTech is strengthening its focus on the Company's growing late-stage oncology pipeline, while continuing its discovery and early research aimed at long-term innovation. Consequently, the Company's shareholders approved expanding the Supervisory Board from six to eight members and adding additional expertise: Prof. Iris Löw-Friedrich
BNTX FAQ
7 questionsWhat does BioNTech SE do?
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen...Where does BNTX stock trade?
BioNTech SE (BNTX) is listed on NASDAQ.What sector and industry is BNTX in?
BioNTech SE operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did BioNTech SE go public?
BioNTech SE (BNTX) completed its IPO in 2019.What are analysts saying about BNTX?
BioNTech SE has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-05-27.What companies are similar to BNTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), RVMD (Revolution Medicines Inc.). Compare BNTX side-by-side with any of them on Quantisnow.How can I track BNTX on Quantisnow?
Quantisnow aggregates BioNTech SE's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BNTX to receive live email and push alerts on every new disclosure.